AUPM747694A0
(en)
*
|
1994-08-16 |
1994-09-08 |
Commonwealth Scientific And Industrial Research Organisation |
Delivery of nucleic acids and peptides
|
CA2220950A1
(en)
*
|
1995-05-26 |
1996-11-28 |
Somatix Therapy Corporation |
Delivery vehicles comprising stable lipid/nucleic acid complexes
|
US5756122A
(en)
*
|
1995-06-07 |
1998-05-26 |
Georgetown University |
Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
|
AU6691496A
(en)
*
|
1995-08-01 |
1997-02-26 |
Advanced Therapies, Inc. |
Enhanced artificial viral envelopes for cellular delivery of therapeutic substances
|
GB9709900D0
(en)
|
1997-05-15 |
1997-07-09 |
Microbiological Res Authority |
Microencapsulated DNA for vaccination and gene therapy
|
JP2000500744A
(ja)
|
1995-11-09 |
2000-01-25 |
マイクロバイオロジカル リサーチ オーソリティー |
ワクチン接種および遺伝子治療のためのマイクロカプセル化dna
|
US6270795B1
(en)
|
1995-11-09 |
2001-08-07 |
Microbiological Research Authority |
Method of making microencapsulated DNA for vaccination and gene therapy
|
JPH09248182A
(ja)
*
|
1996-03-15 |
1997-09-22 |
Oyo Seikagaku Kenkyusho |
プラスミド包埋多重膜リポソーム
|
WO1997042166A1
(fr)
*
|
1996-05-02 |
1997-11-13 |
Terumo Kabushiki Kaisha |
Derives amidines et vecteurs de medicaments les contenant
|
US7384923B2
(en)
|
1999-05-14 |
2008-06-10 |
Lipoxen Technologies Limited |
Liposomes
|
ES2305157T3
(es)
*
|
1996-09-13 |
2008-11-01 |
Lipoxen Technologies Limited |
Liposomas.
|
FR2759382A1
(fr)
*
|
1997-02-10 |
1998-08-14 |
Transgene Sa |
Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
|
US7083786B2
(en)
*
|
1997-04-03 |
2006-08-01 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
GB9810236D0
(en)
|
1998-05-13 |
1998-07-08 |
Microbiological Res Authority |
Improvements relating to encapsulation of bioactive agents
|
US6406719B1
(en)
|
1998-05-13 |
2002-06-18 |
Microbiological Research Authority |
Encapsulation of bioactive agents
|
US6365590B1
(en)
|
1998-05-26 |
2002-04-02 |
Saint Louis University |
Compounds, compositions and methods for treating erectile dysfunction
|
US6124461A
(en)
*
|
1998-05-26 |
2000-09-26 |
Saint Louis University, Health Services Center, Research Administration |
Compounds, compositions, and methods for treating erectile dysfunction
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US6395511B1
(en)
*
|
1998-11-27 |
2002-05-28 |
Darwin Discovery, Ltd. |
Nucleic acids encoding a novel family of TGF-β binding proteins from humans
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
US6458382B1
(en)
*
|
1999-11-12 |
2002-10-01 |
Mirus Corporation |
Nucleic acid transfer complexes
|
ATE274901T1
(de)
|
1999-12-13 |
2004-09-15 |
Lipoxen Technologies Ltd |
Liposomen enthaltend einen komplex aus polyanion und calciumphosphat
|
JP2001316297A
(ja)
*
|
2000-02-23 |
2001-11-13 |
Kaken Pharmaceut Co Ltd |
遺伝子包埋リポソーム製剤及びその製法
|
IL151097A0
(en)
|
2000-02-23 |
2003-04-10 |
Smithkline Beecham Biolog |
Tumour-specific animal proteins
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
ATE442866T1
(de)
|
2000-06-20 |
2009-10-15 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
US7223406B2
(en)
*
|
2000-07-21 |
2007-05-29 |
The Regents Of The University Of California |
Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
|
WO2002007757A2
(en)
*
|
2000-07-21 |
2002-01-31 |
Lue Tom F |
Prevention and treatment of sexual arousal disorders
|
US20020073441A1
(en)
|
2000-12-13 |
2002-06-13 |
Ross Brian D. |
Compositions and methods for detecting proteolytic activity
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
AU2002336760A1
(en)
|
2001-09-26 |
2003-06-10 |
Mayo Foundation For Medical Education And Research |
Mutable vaccines
|
CA2476755C
(en)
|
2001-12-17 |
2014-08-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
US20030219696A1
(en)
*
|
2002-05-23 |
2003-11-27 |
Moreland Gerald W. |
Method and apparatus for preventing backflow in dental saliva evacuators
|
WO2004002453A1
(en)
*
|
2002-06-28 |
2004-01-08 |
Protiva Biotherapeutics Ltd. |
Method and apparatus for producing liposomes
|
US20040224010A1
(en)
*
|
2002-11-15 |
2004-11-11 |
Optime Therapeutics, Inc. |
Ophthalmic liposome compositions and uses thereof
|
RU2389732C2
(ru)
|
2003-01-06 |
2010-05-20 |
Корикса Корпорейшн |
Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
HUE024996T2
(en)
|
2003-05-12 |
2016-01-28 |
Helion Biotech Aps |
Anti-MASP-2 antibodies
|
NZ544618A
(en)
|
2003-06-16 |
2009-02-28 |
Celltech R & D Inc |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
EP2497831B1
(de)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
|
US20060018896A1
(en)
*
|
2004-06-10 |
2006-01-26 |
University Of Leicester |
Methods for treating conditions associated with lectin-dependent complement activation
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
PL1753456T3
(pl)
|
2004-06-10 |
2017-01-31 |
Omeros Corporation |
Sposoby leczenia stanów związanych z aktywacją dopełniacza zależną od masp-2
|
JP2008502622A
(ja)
|
2004-06-14 |
2008-01-31 |
サラマ,ゾーセル,ベー. |
プロリンまたはその誘導体および抗腫瘍抗体からなる抗癌組成物
|
JP2008001598A
(ja)
*
|
2004-10-12 |
2008-01-10 |
Institute Of Physical & Chemical Research |
アポトーシス誘導物質を含む医薬組成物
|
EP1885746B1
(de)
|
2005-02-08 |
2012-01-11 |
Research Development Foundation |
Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
|
WO2006104890A2
(en)
|
2005-03-31 |
2006-10-05 |
Glaxosmithkline Biologicals Sa |
Vaccines against chlamydial infection
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
JP5164830B2
(ja)
|
2005-04-29 |
2013-03-21 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
結核菌感染の予防または治療のための新規方法
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
US7592429B2
(en)
*
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
CA2616877C
(en)
*
|
2005-07-27 |
2014-01-28 |
Protiva Biotherapeutics, Inc. |
Systems and methods for manufacturing liposomes
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
AU2006318212C1
(en)
|
2005-11-23 |
2012-08-30 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
US20090081157A1
(en)
|
2006-01-09 |
2009-03-26 |
Richard Syd Kornbluth |
Immunostimulatory Combinations for Vaccine Adjuvants
|
CA2656228C
(en)
*
|
2006-06-30 |
2016-02-09 |
Hokkaido System Science Co., Ltd. |
Composition for nucleic-acid transfection
|
JP5072275B2
(ja)
|
2006-07-03 |
2012-11-14 |
テルモ株式会社 |
閉鎖小胞の分離方法、製剤の製造方法および評価方法
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
US8652782B2
(en)
|
2006-09-12 |
2014-02-18 |
Longhorn Vaccines & Diagnostics, Llc |
Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
|
JP5080779B2
(ja)
|
2006-10-25 |
2012-11-21 |
テルモ株式会社 |
リポソーム製剤の製造方法
|
US20100015665A1
(en)
*
|
2006-11-10 |
2010-01-21 |
Ucb Pharma S.A. |
Antibodies and diagnostics
|
EP2097450A2
(de)
*
|
2006-11-10 |
2009-09-09 |
Amgen Inc. |
Diagnostika und therapeutika auf antikörperbasis
|
EP3492596A1
(de)
|
2007-04-09 |
2019-06-05 |
University of Florida Research Foundation, Inc. |
Raav-vektorzusammensetzungen mit tyrosinmodifizierten kapsidproteinen und verfahren zu deren verwendung
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
EP2772267B1
(de)
|
2007-08-27 |
2016-04-27 |
Longhorn Vaccines and Diagnostics, LLC |
Immunogene Zusammensetzungen und Verfahren
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
CA2861667C
(en)
|
2007-10-01 |
2017-06-13 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system and methods of use
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
AU2008338464A1
(en)
*
|
2007-12-14 |
2009-06-25 |
Amgen Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
US8753639B2
(en)
|
2009-03-31 |
2014-06-17 |
University Of Washington Through Its Center For Commercialization |
Compositions and methods for modulating the activity of complement regulatory proteins on target cells
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
WO2010138263A2
(en)
|
2009-05-28 |
2010-12-02 |
University Of Massachusetts |
Novel aav 's and uses thereof
|
US8119981B2
(en)
*
|
2009-05-29 |
2012-02-21 |
Micromass Uk Limited |
Mass spectrometer
|
ES2545794T3
(es)
|
2009-08-28 |
2015-09-15 |
Research Development Foundation |
Análogos de urocortina 2 y usos de los mismos
|
BR112012008970A2
(pt)
|
2009-10-16 |
2019-12-10 |
Omeros Corp |
uso de uma composição, e, composição
|
TW201132353A
(en)
|
2009-12-18 |
2011-10-01 |
Amgen Inc |
WISE binding agents and epitopes
|
HUE031184T2
(en)
|
2010-01-27 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Modified tuberculosis antigens
|
ES2711256T3
(es)
|
2010-04-23 |
2019-04-30 |
Univ Florida |
Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のaavベースの治療
|
WO2011133890A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Cns targeting aav vectors and methods of use thereof
|
EA027039B1
(ru)
|
2010-05-14 |
2017-06-30 |
Эмджен Инк. |
Композиции с высокой концентрацией антител
|
HUE037227T2
(hu)
|
2010-05-14 |
2018-08-28 |
Univ Oregon Health & Science |
Rekombináns HCMV és RHCMV vektorok és alkalmazásuk
|
WO2012118903A2
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
CN103517920B
(zh)
|
2011-03-25 |
2018-04-17 |
安进公司 |
抗硬化蛋白(sclerostin)抗体晶体及其制剂
|
MX355648B
(es)
|
2011-04-08 |
2018-04-26 |
Univ Leicester |
El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2.
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
WO2012145624A2
(en)
|
2011-04-21 |
2012-10-26 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
HUE049154T2
(hu)
|
2011-05-04 |
2020-09-28 |
Omeros Corp |
Készítmények a MASP-2-függõ komplement-aktiválás gátlására
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
PT2739311T
(pt)
|
2011-08-04 |
2018-03-26 |
Amgen Inc |
Método para tratamento de defeitos de lacunas ósseas
|
EP2797953B1
(de)
|
2011-12-28 |
2020-06-03 |
Amgen Inc. |
Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
|
CA2863083C
(en)
|
2012-01-26 |
2023-09-19 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
US20130273053A1
(en)
|
2012-04-06 |
2013-10-17 |
University Of Leicester |
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
|
RU2709351C2
(ru)
|
2012-06-18 |
2019-12-17 |
Омерос Корпорейшн |
Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения различных заболеваний и нарушений
|
AU2013285488B2
(en)
|
2012-07-05 |
2018-03-22 |
Ucb Pharma S.A. |
Treatment for bone diseases
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
MX2015009901A
(es)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administración de un compuesto de antiactivina a a un sujeto.
|
JP6549554B2
(ja)
|
2013-03-15 |
2019-07-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
コレステロール流出を刺激する、減少した毒性を有するペプチド
|
BR112015023502A2
(pt)
|
2013-03-15 |
2017-07-18 |
Glaxosmithkline Biologicals Sa |
composição, e, métodos para intensificar uma resposta imune e melhorar ou prevenir substancialmente uma doença infecciosa, uma doença autoimune, ou uma condição alérgica em um indivíduo
|
DK3057993T3
(en)
|
2013-10-17 |
2020-11-16 |
Omeros Corp |
Method for Treating Conditions Associated with MASP-2 Dependent Complement
|
AU2015231294B2
(en)
|
2014-03-18 |
2020-10-29 |
University Of Massachusetts |
rAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
WO2015164786A1
(en)
|
2014-04-25 |
2015-10-29 |
University Of Massachusetts |
Recombinant aav vectors useful for reducing immunity against transgene products
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
EP3207150B1
(de)
|
2014-10-14 |
2021-04-28 |
Research Development Foundation |
Verfahren zur erzeugung von manipulierten enzymen
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
US10695417B2
(en)
|
2015-01-09 |
2020-06-30 |
Etubics Corporation |
Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
|
CA3019315A1
(en)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation of aav vector transgene expression
|
CA2985652C
(en)
|
2015-05-14 |
2020-03-10 |
Gerald W. FISHER |
Rapid methods for the extraction of nucleic acids from biological samples
|
WO2017083371A1
(en)
|
2015-11-09 |
2017-05-18 |
Omeros Corporation |
Methods for treating conditions associated with masp-2 dependent complement activation
|
EP3383418B1
(de)
|
2015-12-04 |
2021-10-20 |
Board of Regents, The University of Texas System |
Slc45a2-peptide für immuntherapie
|
SG11201805695SA
(en)
|
2016-01-05 |
2018-07-30 |
Univ Leicester |
Methods for inhibiting fibrosis in a subject in need thereof
|
EP4094780A3
(de)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
|
KR102336362B1
(ko)
|
2016-03-03 |
2021-12-08 |
보이저 테라퓨틱스, 인크. |
비-바이러스 유전자 전달을 위한 폐쇄형-말단 선형 듀플렉스 dna
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
CN115137816A
(zh)
|
2016-03-31 |
2022-10-04 |
奥默罗斯公司 |
抑制有需要的受试者的血管发生的方法
|
JP7262100B2
(ja)
|
2016-04-29 |
2023-04-21 |
アイカーン スクール オブ メディスン アット マウント サイナイ |
長期寛容を誘導するためのおよびアテローム性動脈硬化症におけるマクロファージ蓄積を解決するための自然免疫システムの標的化
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
US20190185864A1
(en)
|
2016-08-23 |
2019-06-20 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
CA3059112A1
(en)
|
2017-04-05 |
2018-10-11 |
University Of Massachusetts |
Cep290 minigene therapy
|
US20200138921A1
(en)
|
2017-06-23 |
2020-05-07 |
The Trustees Of Columbia University In The City Of New York |
Methods of preventing and treating diseases characterized by synaptic dysfunction and neurodegeneration including alzheimer's disease
|
TW202402809A
(zh)
|
2017-08-15 |
2024-01-16 |
美商歐米諾斯公司 |
用於治療和/或預防與造血幹細胞移植有關的移植物抗宿主病和/或瀰漫性肺泡出血和/或靜脈閉塞性病的方法
|
KR20200135433A
(ko)
|
2018-03-23 |
2020-12-02 |
유니버시티 오브 매사추세츠 |
골 장애 치료를 위한 유전자 치료제
|
KR20200138254A
(ko)
|
2018-03-30 |
2020-12-09 |
암젠 인크 |
C-말단 항체 변이체
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
MX2021003663A
(es)
|
2018-09-28 |
2021-05-28 |
Harvard College |
Reprogramacion celular para revertir el envejecimiento y promover la regeneracion de organos y tejidos.
|
CN113164625A
(zh)
|
2018-09-28 |
2021-07-23 |
哈佛大学的校长及成员们 |
用于基因表达的突变体反向四环素反式激活因子
|
US20220033824A1
(en)
|
2018-11-29 |
2022-02-03 |
University Of Massachusetts |
Modulation of sptlc1 via recombinant adeno-associated vectors
|
EP3927380A1
(de)
|
2019-02-22 |
2021-12-29 |
University of Massachusetts |
Oxr1-gentherapie
|
EP3959232A4
(de)
|
2019-04-24 |
2023-01-18 |
University of Massachusetts |
Aav-capsid-chimäre antigenrezeptoren und verwendungen davon
|
KR20220079857A
(ko)
|
2019-09-13 |
2022-06-14 |
루트거스, 더 스테이트 유니버시티 오브 뉴 저지 |
Aav-상용성 라미닌-링커 중합 단백질
|
WO2021101265A1
(ko)
*
|
2019-11-22 |
2021-05-27 |
주식회사 삼양바이오팜 |
약물전달용 나노입자 조성물 제조용 키트
|
JP2023504543A
(ja)
|
2019-12-04 |
2023-02-03 |
オメロス コーポレーション |
Masp-2阻害剤および使用方法
|
CA3168055A1
(en)
|
2020-02-21 |
2021-08-26 |
Emmanuel John Simons |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
EP4127186A1
(de)
|
2020-03-24 |
2023-02-08 |
Generation Bio Co. |
Nichtvirale dna-vektoren und verwendungen davon zur expression von gaucher-therapeutika
|
MX2022012279A
(es)
|
2020-03-31 |
2023-02-23 |
Univ Massachusetts |
Variantes de capsides de aav y usos de los mismos.
|
EP4150626A1
(de)
|
2020-04-29 |
2023-03-22 |
The Broad Institute Inc. |
Durch maschinelles lernen beschleunigte proteinzüchtung durch fitnessvorhersage
|
AU2021275239A1
(en)
|
2020-05-21 |
2022-12-15 |
Board Of Regents, The University Of Texas System |
T cell receptors with VGLL1 specificity and uses thereof
|
IL300526A
(en)
|
2020-08-17 |
2023-04-01 |
Massachusetts Inst Technology |
Approaches to SHANK3 gene therapy
|
EP4255457A1
(de)
|
2020-12-03 |
2023-10-11 |
University of Massachusetts |
Entwicklung von neuen gentherapeutika für fibrodysplasia ossificans progressiva
|
WO2022198101A1
(en)
|
2021-03-19 |
2022-09-22 |
Trained Therapeutix Discovery, Inc. |
Compounds for regulating trained immunity, and their methods of use
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
IL308404A
(en)
|
2021-04-27 |
2024-01-01 |
Generation Bio Co |
Non-viral DNA vectors expressing therapeutic antibodies and uses thereof
|
KR20240017813A
(ko)
|
2021-05-10 |
2024-02-08 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
신경질환 치료용 약학적 조성물
|
CA3233097A1
(en)
|
2021-09-30 |
2023-04-06 |
Katherine Diane GRIBBLE |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|